This study is a Phase II, randomized, crossover trial designed to compare one fixed dose of
dabigatran with open-label use of ASA in patients affected by CADASIL; the study is a safety
trial, and the primary objective is to assess that dabigatran is not less safe than ASA in
subjects with CADASIL.